Articles Tagged with ''ALS''

Conceptual 3D illustration showing degradation of motor neuron
Neurology/psychiatric

Alchemab and Lilly sign licensing agreement for ATLX-1282

May 6, 2025
No Comments
Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
Read More
Neurology/psychiatric

Voyager to evaluate alternate payloads for ALS gene therapy program

Feb. 12, 2025
Voyager Therapeutics Inc. has announced its decision to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). Emerging preclinical data indicate the siRNA payload component of VY-9323 does not meet its standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window.
Read More
Degradation of motor neurons
Neurology/psychiatric

Lifearc and Neuropeutics collaborate to advance small molecule for ALS

Jan. 28, 2025
Lifearc has announced a collaboration with Neuropeutics Inc. to develop a new small molecule for the treatment of motor neuron disease (MND), or amyotrophic lateral sclerosis (ALS). Neuropeutics and Lifearc intend to develop a lead candidate therapeutic to prevent and reverse TDP-43 protein aggregation in MND/ALS.
Read More
Central nervous system
Neurology/psychiatric

Bristol Myers Squibb selects novel ALS target under Insitro collaboration

Dec. 19, 2024
Bristol Myers Squibb Co. has selected the first novel target for amyotrophic lateral sclerosis (ALS) that was identified and validated by Insitro Inc. under the companies’ 2020 collaboration agreement to discover new therapies for ALS. The selection triggers a milestone payment to Insitro.
Read More